Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry.
A HPLC-MS-MS method was developed and validated to measure lamivudine and zidovudine simultaneously in small volumes of human seminal plasma. Sample preparation was simple and rapid, requiring 25 microl of sample, the use of isotopically labeled lamivudine and zidovudine as internal standards and ultrafiltration through a molecular mass cut-off membrane. Lamivudine and its internal standard were separated from zidovudine and its internal standard with isocratic HPLC. Detection was carried out using tandem mass spectrometry. This validated method was used to analyze seminal samples obtained from six HIV-positive patients prescribed lamivudine and zidovudine.
Pereira
A S
AS
Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill 27599, USA.
Kenney
K B
KB
Cohen
M S
MS
Hall
J E
JE
Eron
J J
JJ
Tidwell
R R
RR
Dunn
J A
JA
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000032:analysis / Q000627:therapeutic use; D002138:Calibration; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000032:analysis* / Q000627:therapeutic use; D008297:Male; D013058:Mass Spectrometry / Q000379:methods*; D012015:Reference Standards; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000032:analysis* / Q000627:therapeutic use; D012661:Semen / Q000737:chemistry*; D015215:Zidovudine / Q000008:administration & dosage / Q000032:analysis* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine